Early data from the KYANITE-1 study support the RMAT designation for KB707 as a treatment for those with advanced or metastatic NSCLC.
Justin Mancini
Advertisement
Articles by Justin Mancini
Advertisement
Latest Updated Articles
FDA Grants RMAT Designation to HSV-Based Immunotherapy in NSCLCFebruary 9th 2026
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
Navigating New Horizons in Neuroendocrine Prostate Cancer
4
The Intersection of Technology and Psycho-Oncology Care
5